IOD completes acquisition of Confidential Copiers

NewsGuard 100/100 Score

IOD Incorporated™, a leading provider of integrated HIM solutions to hospitals, health systems, and physician practices, today announced the completion of a strategic acquisition of Confidential Copiers Inc. (CCI). The combination brings a full suite of end-to-end HIM service solutions to a greatly expanded Colorado market place.

"As the second largest release of information (ROI) providers nationwide, IOD continues to execute our strategic plan, which includes expansion of service solutions, best of breed resources and geographical expertise," says Mike Wickman, Chairman and CEO of IOD. "CCI brings all three of these aspects to the ROI business and greatly expands our presence in the Rocky Mountain region." He adds, "Their philosophy of putting clients first and delivering quality service blends perfectly with the IOD culture."

When Cindy Reitz, President and CEO of CCI, was asked why IOD, she responded, "We have been approached by many companies over the years, but IOD brought a compatibility that we saw in no other company. They have great brand recognition in our area, cutting edge technology for our ROI customers, a superior customer service reputation, and after meeting with them, we saw the excellent fit of the two companies. CCI customers are also excited about the new coding and imaging services that are now available with the addition of IOD."

Source:

IOD Incorporated

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows ritonavir-boosted nirmatrelvir remains effective against new omicron variants in the U.S